The full edition of the report is available at Xinhua Silk Road Database. You can click the “Table of Content” to have a general understanding of it.
Click on the button below to create your account and get immediate access to thousands of articles.
China Focus: China's drug innovation rises faster, with broader share in global market
At the end of April, Andamertinib Benzoate Capsules, an independently developed Chinese medication for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer, received market approval from China's National Medical Products Administration (NMPA).
May29,2026
China sees advance in anti-tumor drug approval
China has seen robust growth in its number of new anti-tumor drug approvals during the 13th Five-Year Plan (2016-2020) period, according to the National Medical Products Administration (NMPA).
April01,2021
If you have any questions, please enter them in the box below.
Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to silkroadweekly@xinhua.org and share your stories with more people.
Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.
